Abstract
Early optimism for the chemotherapeutic augmentation of standard surgical treatment of gastric cancer has thus far generally not come to pass. First attempts to destroy circulating cancer cells in small metastatic foci by giving drugs at the completion of operation and in the immediate postoperative period were disappointing. Numerous large cooperative groups and individual institutions are now studying drugs and drug combinations in various treatment regimens and have introduced the use of radiotherapy and immunotherapy in an effort to improve long-term survival following surgical resection of gastric cancer. Resurgence of interest in surgical adjuvant studies, and especially recent encouraging results from drug and immunotherapy, generates optimism that the theoretical potential of this approach to cancer control may soon be realized.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
